Cargando…

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland

Metastatic melanoma is a highly aggressive disease. Recent progress in immunotherapy (IT) and targeted therapy (TT) has led to significant improvements in response and survival rates in metastatic melanoma patients. The current project aims to determine the benefit of the introduction of these new t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mangana, Joanna, Cheng, Phil F., Kaufmann, Corina, Amann, Valerie C., Frauchiger, Anna L., Stögner, Viola, Held, Ulrike, von Moos, Roger, Michielin, Olivier, Braun, Ralph P., Levesque, Mitchell P., Goldinger, Simone M., Dummer, Reinhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	ORIGINAL ARTICLES: Clinical research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5633326/ https://www.ncbi.nlm.nih.gov/pubmed/28509765 http://dx.doi.org/10.1097/CMR.0000000000000359

Ejemplares similares

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
por: Mangana, Joanna, et al.
Publicado: (2015)

Sarcoid-like reactions in patients receiving modern melanoma treatment
por: Dimitriou, Florentia, et al.
Publicado: (2018)

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
por: Krähenbühl, Lukas, et al.
Publicado: (2018)

The role of cyclin D1 and Ki‐67 in the development and prognostication of thin melanoma
por: Kaufmann, Corina, et al.
Publicado: (2020)

Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis
por: Dimitriou, Florentia, et al.
Publicado: (2021)

Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2022)

Addendum: Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2023)

How I treat metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2019)

Melanoma patients with additional primary cancers: a single-center retrospective analysis
por: Dimitriou, Florentia, et al.
Publicado: (2019)

Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis
por: Ziegler, Johanna S., et al.
Publicado: (2020)

Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Dummer, Reinhard, et al.
Publicado: (2009)

A practical guide to the handling and administration of talimogene laherparepvec in Europe
por: Harrington, Kevin J, et al.
Publicado: (2017)

Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy
por: DIMITRIOU, Florentia, et al.
Publicado: (2020)

Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2018)

Diffuse Cutaneous Melanosis Associated with Malignant Melanoma
por: Mangana, Joanna, et al.
Publicado: (2015)

Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma
por: Fröhlich, Fabienne, et al.
Publicado: (2023)

A new B-Raf inhibitor combo for advanced melanoma
por: Barysch, Marjam-Jeanette, et al.
Publicado: (2018)

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
por: Goldinger, Simone M., et al.
Publicado: (2013)

Unexpected contribution of lymphatic vessels to promotion of distant metastatic tumor spread
por: Ma, Qiaoli, et al.
Publicado: (2018)

Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis
por: Kraehenbuehl, Lukas, et al.
Publicado: (2023)

Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome)
por: Mangana, Joanna, et al.
Publicado: (2017)

Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice
por: Mangana, Joanna, et al.
Publicado: (2022)

Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
por: Pham, James P., et al.
Publicado: (2023)

Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830
por: Kudura, Ken, et al.
Publicado: (2022)

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
por: Fässler, Mirjam, et al.
Publicado: (2019)

Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma
por: Cheng, Phil F, et al.
Publicado: (2015)

Long‐Term Response to Intermittent Binimetinib in Patients with NRAS‐Mutant Melanoma
por: Matter, Alexandra Valeska, et al.
Publicado: (2020)

Loss of YY1, a Regulator of Metabolism in Melanoma, Drives Melanoma Cell Invasiveness and Metastasis Formation
por: Guendisch, Ulf, et al.
Publicado: (2022)

The Prognostic Value of a Single, Randomly Timed Circulating Tumor DNA Measurement in Patients with Metastatic Melanoma
por: Boerlin, Aurelio, et al.
Publicado: (2022)

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
por: Ressler, Julia Maria, et al.
Publicado: (2021)

Standardized diagnostic algorithm for spitzoid lesions aids clinical decision-making and management: a case series from a Swiss reference center
por: Hilbers, Marie-Luise, et al.
Publicado: (2021)

Addendum: Standardized diagnostic algorithm for spitzoid lesions aids clinical decision-making and management: a case series from a Swiss reference center
por: Hilbers, Marie-Luise, et al.
Publicado: (2022)

Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown
por: Kostner, Lisa, et al.
Publicado: (2022)

Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy
por: Nosrati, Adi, et al.
Publicado: (2017)

Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
por: Dummer, Reinhard, et al.
Publicado: (2017)

Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2(S310F) mutated extramammary Paget’s disease
por: Nordmann, Thierry M., et al.
Publicado: (2019)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
por: Welti, Michèle, et al.
Publicado: (2022)

Modelling the effect of a border closure between Switzerland and Italy on the spatiotemporal spread of COVID-19 in Switzerland
por: Grimée, Mathilde, et al.
Publicado: (2022)

Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients
por: Goldinger, Simone M, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hak77c7oc5u0rbghb0kfel7oqp